Protocols · Weight Management · Tirzepatide
Research Protocol · Educational

Tirzepatide
30 mg Vial Protocol

Tirzepatide is dosed once a week under the skin. For the 30 mg vial, you'll find the reconstitution math, the FDA-approved Mounjaro/Zepbound titration for reference, and syringe-unit conversions below, with every figure sourced to the protocol guide and peer-reviewed literature cited.

Tirzepatide
Tirzepatide · 30 mg · research use only
Approved dose range
2.5–10 mg/week
Reconstitute
3.0 mL BAC water
Concentration
10.0 mg/mL
Storage
2–8 °C · ≤28 days
Dosage

Dosage Chart

Regulatory note. Tirzepatide is FDA-approved for multiple indications: as Mounjaro, an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; and as Zepbound, for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and as the first FDA-approved medication for moderate-to-severe obstructive sleep apnea in adults with obesity. [4] The titration below is sourced to a research vial dosage protocol, not directly to the Mounjaro/Zepbound prescribing label; the sourced schedule matches the approved product's early titration steps, but the dossier reviewed for this page does not confirm whether it covers the complete approved dosing range. Consult the approved product labeling for the full FDA-authorized dosing range.

Once-weekly subcutaneous injection, on the same day each week. [5] The dossier used for this page describes a single dosing schedule, framed as the approved range; no separate off-label or investigational schedule is given in the source reviewed here.

PhaseWeekly doseUnits (U-100)Volume
Weeks 1–4 (initiation)2.5 mg25 u0.25 mL
Weeks 5–85.0 mg50 u0.50 mL
Weeks 9–127.5 mg75 u0.75 mL
Weeks 13–16+ (maintenance)10.0 mg100 u1.00 mL

The 10.0 mg/100-unit dose fills the entire volume of a standard 1 mL/100-unit syringe. This titration escalates over 16 weeks. [5]

Prep

Reconstitution

30 mg vial, mixed to a working concentration before drawing a dose.

Add 3.0 mL of bacteriostatic water to the 30 mg vial to yield a final concentration of 10.0 mg/mL. At this concentration, 1 unit on a U-100 insulin syringe equals 0.01 mL, or 100 mcg of tirzepatide. [5]

Store the lyophilized vial at −20 °C in dry, dark conditions. Once reconstituted, refrigerate at 2–8 °C and do not freeze; use within 28 days. [5]

Mechanism

How It Works

Tirzepatide is a synthetic peptide engineered to activate two incretin receptors, the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, with a pharmacokinetic profile designed for once-weekly administration. [4]

In head-to-head SURPASS trials, tirzepatide showed greater reductions in A1C and body weight compared with semaglutide 1 mg. [4] A related analysis found that after tirzepatide treatment, approximately 60% of adults with type 2 diabetes shifted to a lower, improved BMI category, with documented cardiometabolic improvements. [1] In SURMOUNT-1, once-weekly tirzepatide produced substantial mean body weight reductions in adults with obesity or overweight; [4] a post hoc analysis of the SURMOUNT trials found that tirzepatide achieved combined thresholds of body-weight reduction, systolic blood pressure reduction of at least 5 mmHg, and non-HDL cholesterol below 130 mg/dL in people with obesity, with or without type 2 diabetes. [2] A separate literature review examined whether tirzepatide, used as an anti-diabetic agent, could affect cancer risk in patients with diabetes and cancer, without reaching a settled conclusion either way. [3]

Gastrointestinal effects, nausea, diarrhea, vomiting, and constipation, are the most frequently reported adverse effects. [4] Tirzepatide is FDA-approved under the brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management; moderate-to-severe obstructive sleep apnea in adults with obesity). [4] This section describes what the cited literature reports; it is not a claim of safety or effectiveness beyond the approved indications.

Evidence

References

[1] Improvement in BMI Category Associated With Cardiometabolic Measures in Type 2 Diabetes Treated With Tirzepatide · PMID 40707399

[2] Achieving the Triple Endpoint With Tirzepatide in People With Obesity · SURMOUNT post hoc analysis, PMID 42594122

[3] Tirzepatide, Friend or Foe in Diabetic Cancer Patients? · PMID 36358930

[4] Tirzepatide overview · PeptideDosages

[5] Tirzepatide 30 mg vial dosage protocol · PeptideDosages

Educational use only. This content is for research and educational purposes only and is not medical advice, diagnosis, or treatment. Tirzepatide is FDA-approved under the brand names Mounjaro and Zepbound for the specific indications described above; this page reflects current regulatory status as of 2026. Any use outside an approved indication should involve a qualified healthcare provider, and this page is not intended to replace the approved product's prescribing information.